Japanese Government Procurement
National University Corporation - Notice of Procurement (Goods & Services)Sotatercept (Genetical Recombination) 45mg 1vial/case about 20cases,and 17 other contracts
This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.
| Publishing date | Oct 01, 2026 |
|---|---|
| Type of notice | Notice of Procurement (Goods & Services) |
| Procurement entity | National University Corporation - Ibaraki |
| Classification |
0004 Medical & Pharmaceutical Products |
| Summay of notice | ⑴ Official in charge of disbursement of the procuring entity : HIRAMATSU Yuji, The Obligating Officer Director, University of Tsukuba Hospital ⑵ Classification of the products to be procured : 4 ⑶ Nature and quantity of the products to be purchased : A Sotatercept (Genetical Recombination) 45mg 1vial/case about 20cases B Sotatercept (Genetical Recombination) 60mg 1vial/case about 10cases C Tagraxofusp (Genetical Recombination) 1000µg 1vial/case about 5cases D Satralizumab (Genetical Recombination) 120mg 1vial/case about 30cases E Abatacept (Genetical Recombination) 250mg 1vial/case about 200cases F Talquetamab (Genetical Recombination) 40mg 1vial/case about 5cases G Daratumumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) 15mL 1vial/case about 180cases H Teclistamab (Genetical Recombination) 153mg 1vial/case about 5cases I Guselkumab (Genetical Recombination) 200mg/2mL 1kit/case about 40cases J Sacituzumab Govitecan (Genetical Recombination) 200mg 1vial/case about 70cases K Enfortumab Vedotin (Genetical Recombination) 20mg 1vial/case about 80cases L Enfortumab Vedotin (Genetical Recombination) 30mg 1vial/case about 180cases M Azacitidine 100mg 1vial/case about 490cases N Nirsevimab (Genetical Recombination) 100mg/1mL 1syringe/case about 20cases O Nirsevimab (Genetical Recombination) 50mg/0.5mL 1syringe/case about 50cases P Bevacizumab (Genetical Recombination) 400mg/16mL 1vial/case about 290cases Q Amivantamab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) 10mL 1vial/case about 20cases R Mosunetuzumab (Genetical Recombination) 45mg 1vial/case about 10cases ⑷ Delivery period : From 1 January, 2027 through 31 March, 2027 ⑸ Delivery place : The University of Tsukuba Hospital ⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall : A not come under Article 46 and 47 of the Regulation concerning the Contract for University of Tsukuba Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause, B have the Grade A, Grade B or Grade C qualification during fiscal 2026 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency, or in tenders by University of Tsukuba, C prove to have obtained a license for wholesale distribution of pharmaceuticals under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by The Obligating Officer Director, E meet the qualification requirements which The Obligating Officer Director may specify in accordance with Article 49 of the Regulation, F not be currently under a suspension of business order as instructed by The Obligating Officer. ⑺ Time limit of tender : 10 : 00 26 November, 2026 ⑻ Contact point for the notice : MURASAWA Yuki, Division of Accounting, Department of University Hospital Management, University of Tsukuba, 2-1-1 Amakubo Tsukuba-shi 305-8576 Japan, TEL 029-853-3543 ⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents. |
